HEAT BIOLOGICS INC (HTBX) Stock News

USA - NYSEARCA:HTBX - US42237K4094 - Common Stock

2.38

+0.01 (+0.42%)

Last: 5/2/2022, 8:04:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

HTBX Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Heat Biologics - Mentions: NHWK

NightHawk Biosciences Provides First Quarter 2022 Business Update

3 years ago - By: Heat Biologics - Mentions: NHWK

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today

3 years ago - By: Heat Biologics - Mentions: NHWK

Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics

3 years ago - By: Heat Biologics - Mentions: NHWK

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

3 years ago - By: Benzinga

Heat Biologics' Subsidiary Outlines Development of New Commercial/Biodefense Biomanufacturing Facility

4 years ago - By: Benzinga

Heat Biologics' Merger Partner Elusys Finalizes HHS Contract For Its Anthrax Treatment

3 years ago - By: Heat Biologics

Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility

3 years ago - By: Heat Biologics

Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

4 years ago - By: Heat Biologics

Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

4 years ago - By: Heat Biologics

Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company

4 years ago - By: Analyst Ratings

News Image

Maxim Group Thinks Heat Biologics’ Stock is Going to Recover

4 years ago - By: Heat Biologics

Heat Biologics Announces Planned Transfer to the NYSE American

4 years ago - By: Heat Biologics

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

4 years ago - By: Heat Biologics

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

4 years ago - By: Heat Biologics

Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

4 years ago - By: Heat Biologics

Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy